Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 714

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 3
Chunk 714
---
ing”), entering into securities purchase agreements with
a small group of accredited investors. The Company’s Chief Executive Officer, Anatoly Dritschilo,
invested $237,500 in the Offering.

On
October 21, 2024, the Company closed on an additional $231,579 in Notes and Warrants purchased in the Offering (the “Second Closing”),
receiving an additional $220,000 in proceeds and bringing the Offering to a close after receiving a total of $790,000 in gross proceeds,
including $237,500 invested by the Company’s Chief Executive Officer in the First Closing. In the Second
Closing, two accredited investors purchased a total of $231,579 in Notes and 88,544 Warrants, exercisable at $1.49 per share, or 125%
of the closing price of the Company’s common stock on the day prior to closing. The Company received total net proceeds of $682,510
from the Offering. To date, the warrants from the Offering have yet to be exercised.

On
October 31, 2024, the Company consummated a public offering of an aggregate of (i) 395,574 Shares of
common stock, and 2,555,246 Pre-Funded Warrants to purchase up to 2,555,246 shares of common stock, and (ii) 2,950,820 Common Warrants
to purchase up to 2,950,820 Common Warrant Shares. Each share of common stock, or Pre-Funded Warrant in lieu thereof, was sold together
with an accompanying Common Warrant to purchase one share of common stock. The public offering price for each share of common stock and
one accompanying Common Warrant was $1.525. The public offering price of each Pre-Funded Warrant and one accompanying Common Warrant
was $1.524, which equals the price at which one share of common stock and accompanying Common Warrant was sold to the public in the offering,
minus $0.001. The exercise price of each Pre-Funded Warrant is $0.001 per share. Each Common Warrant offered in the offering is exercisable
for one share of common stock and has an initial exercise price equal to $1.40. The Company received aggregate gross proceeds from the
offering of approximately $4.5 million, before deducting placement agents’ fees and other offering expenses. A.G.P./Alliance Global
Partners and Boustead served as placement